Emergent BioSolutions Inc. (EBS) Financial Ratios
25 years of historical data (2001–2025) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
↓
3.74
↓-31% vs avg
5yr avg: 5.44
30Y Low2.7·High24.5
P/FCF
↓
2.63
↓-82% vs avg
5yr avg: 14.36
30Y Low4.5·High28.0
P/B Ratio
↓
0.87
-3% vs avg
5yr avg: 0.89
30Y Low0.2·High4.0
ROE
↓
10.5%
↓+154% vs avg
5yr avg: -19.5%
30Y Low-75%·High50%
Debt/EBITDA
↑
2.74
+18% vs avg
5yr avg: 2.32
30Y Low0.1·High5.2
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
EBS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Emergent BioSolutions Inc. trades at 8.6x earnings, 28% below its 5-year average of 12.0x, sitting at the 6th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a discount of 61%. On a free-cash-flow basis, the stock trades at 2.6x P/FCF, 82% below the 5-year average of 14.4x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $413M | $701M | $507M | $123M | $592M | $2.4B | $4.8B | $2.8B | $3.0B | $2.3B | $1.6B |
| Enterprise Value | $780M | $1.1B | $1.1B | $871M | $1.4B | $2.6B | $5.1B | $3.5B | $3.7B | $2.2B | $1.6B |
| P/E Ratio → | 8.60 | 13.29 | — | — | — | 10.71 | 15.80 | 51.88 | 48.59 | 27.18 | 29.06 |
| P/S Ratio | 0.56 | 0.94 | 0.49 | 0.12 | 0.53 | 1.33 | 3.06 | 2.56 | 3.89 | 4.17 | 3.31 |
| P/B Ratio | 0.87 | 1.34 | 1.05 | 0.19 | 0.43 | 1.46 | 3.33 | 2.60 | 3.01 | 2.56 | 2.72 |
| P/FCF | 2.63 | 4.47 | 14.15 | — | — | 24.47 | 12.20 | 27.96 | — | 15.25 | — |
| P/OCF | 2.42 | 4.11 | 8.63 | — | — | 7.32 | 8.98 | 15.04 | 72.89 | 11.24 | 30.29 |
P/E links to full P/E history page with 30-year chart
EBS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Emergent BioSolutions Inc.'s enterprise value stands at 3.7x EBITDA, 31% below its 5-year average of 5.4x. The Healthcare sector median is 14.2x, placing the stock at a 74% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.44 | 1.04 | 0.83 | 1.23 | 1.49 | 3.25 | 3.16 | 4.77 | 3.88 | 3.31 |
| EV / EBITDA | 3.74 | 5.12 | — | — | — | 5.76 | 9.34 | 15.74 | 24.54 | 13.03 | 11.25 |
| EV / EBIT | 7.08 | 9.69 | — | — | — | 6.86 | 10.26 | 23.17 | 40.14 | 16.46 | 17.07 |
| EV / FCF | — | 6.81 | 30.26 | — | — | 27.54 | 12.97 | 34.58 | — | 14.18 | — |
EBS Profitability
Margins and return-on-capital ratios measuring operating efficiency
Emergent BioSolutions Inc. earns an operating margin of 14.8%. Operating margins have expanded from -69.2% to 14.8% over the past 3 years, signaling improving operational efficiency. ROE of 10.5% is modest. ROIC of 8.5% represents adequate returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 47.2% | 47.2% | 36.0% | 34.3% | 42.3% | 44.7% | 54.7% | 43.7% | 41.0% | 50.6% | 50.1% |
| Operating Margin | 14.8% | 14.8% | -10.4% | -69.2% | -15.2% | 19.2% | 27.8% | 10.3% | 11.5% | 22.2% | 21.6% |
| Net Profit Margin | 7.1% | 7.1% | -18.3% | -72.5% | -18.9% | 12.4% | 19.4% | 4.9% | 8.0% | 14.7% | 10.6% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 10.5% | 10.5% | -33.7% | -74.7% | -14.1% | 14.4% | 24.1% | 5.2% | 6.5% | 11.0% | 8.2% |
| ROA | 3.9% | 3.9% | -11.9% | -30.5% | -6.9% | 7.5% | 11.7% | 2.4% | 3.8% | 8.1% | 5.1% |
| ROIC | 8.5% | 8.5% | -6.6% | -30.5% | -6.3% | 14.0% | 18.8% | 5.0% | 5.5% | 13.9% | 13.3% |
| ROCE | 9.1% | 9.1% | -9.1% | -46.7% | -7.5% | 13.4% | 19.0% | 5.5% | 6.0% | 13.6% | 11.7% |
EBS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Emergent BioSolutions Inc. carries a Debt/EBITDA ratio of 2.7x, which is moderately leveraged (15% below the sector average of 3.2x). Net debt stands at $367M ($572M total debt minus $205M cash). Interest coverage of just 1.9x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.09 | 1.09 | 1.40 | 1.32 | 1.03 | 0.54 | 0.64 | 0.77 | 0.79 | 0.01 | 0.45 |
| Debt / EBITDA | 2.74 | 2.74 | — | — | — | 1.90 | 1.68 | 3.77 | 5.23 | 0.08 | 1.87 |
| Net Debt / Equity | — | 0.70 | 1.19 | 1.15 | 0.56 | 0.18 | 0.21 | 0.61 | 0.68 | -0.18 | -0.01 |
| Net Debt / EBITDA | 1.76 | 1.76 | — | — | — | 0.64 | 0.55 | 3.01 | 4.49 | -0.99 | -0.02 |
| Debt / FCF | — | 2.34 | 16.11 | — | — | 3.07 | 0.76 | 6.62 | — | -1.08 | — |
| Interest Coverage | 1.86 | 1.86 | -0.74 | -1.91 | -2.93 | 11.19 | 15.95 | 3.93 | 9.38 | 20.05 | 12.43 |
EBS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Emergent BioSolutions Inc.'s current ratio of 5.01x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 2.41x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 1.04x to 5.01x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.01 | 5.01 | 3.69 | 1.04 | 0.98 | 3.40 | 3.11 | 3.17 | 3.10 | 4.85 | 4.82 |
| Quick Ratio | 2.41 | 2.41 | 1.77 | 0.54 | 0.70 | 2.47 | 2.31 | 2.14 | 2.07 | 3.42 | 4.12 |
| Cash Ratio | 1.55 | 1.55 | 0.61 | 0.17 | 0.52 | 1.54 | 1.62 | 0.78 | 0.56 | 1.78 | 2.56 |
| Asset Turnover | — | 0.56 | 0.75 | 0.58 | 0.35 | 0.60 | 0.55 | 0.48 | 0.35 | 0.52 | 0.50 |
| Inventory Turnover | 1.14 | 1.14 | 2.14 | 2.10 | 1.84 | 2.85 | 2.33 | 2.80 | 2.24 | 1.94 | 3.30 |
| Days Sales Outstanding | — | 41.37 | 54.04 | 66.44 | 52.00 | 57.40 | 53.43 | 90.85 | 122.46 | 95.07 | 110.87 |
EBS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Emergent BioSolutions Inc. returns 6.0% to shareholders annually primarily through share buybacks. The earnings yield of 11.6% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 11.6% | 7.5% | — | — | — | 9.3% | 6.3% | 1.9% | 2.1% | 3.7% | 3.4% |
| FCF Yield | 38.0% | 22.4% | 7.1% | — | — | 4.1% | 8.2% | 3.6% | — | 6.6% | — |
| Buyback Yield | 6.0% | 3.6% | 0.0% | 0.0% | 13.9% | 4.5% | 0.0% | 0.0% | 0.0% | 1.4% | 0.1% |
| Total Shareholder Yield | 6.0% | 3.6% | 0.0% | 0.0% | 13.9% | 4.5% | 0.0% | 0.0% | 0.0% | 1.4% | 0.1% |
| Shares Outstanding | — | $57M | $53M | $51M | $50M | $54M | $54M | $52M | $51M | $50M | $49M |
Peer Comparison
Compare EBS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 EBSYou | $413M | 8.6 | 3.7 | 2.6 | 47.2% | 14.8% | 10.5% | 8.5% | 2.7 |
 SIGA | $310M | 13.1 | 6.4 | 7.2 | 68.6% | 25.1% | 11.2% | 33.7% | 0.0 |
 PRGO | $1B | -1.0 | 7.1 | 9.8 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
 BRKR | $9B | -381.5 | 22.9 | 201.2 | 45.9% | 6.9% | -0.4% | 4.4% | 4.5 |
 ABCL | $2B | -11.3 | — | — | 61.6% | -289.0% | -13.3% | -15.5% | — |
 PCRX | $878M | 139.6 | 9.4 | 6.4 | 79.4% | 4.6% | 1.0% | 2.3% | 3.7 |
 PFE | $143B | 18.5 | 10.3 | 15.8 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
 MRK | $281B | 15.6 | 10.8 | 22.8 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
 JNJ | $550B | 39.4 | 19.1 | 27.7 | 69.1% | 24.9% | 20.1% | 20.7% | 1.2 |
 BAX | $10B | -11.4 | 27.2 | 31.8 | 30.1% | -2.7% | -14.6% | -1.4% | 14.9 |
 MCK | $90B | 19.6 | 13.2 | 15.8 | 3.6% | 1.6% | — | 254.1% | 1.2 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 23 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
EBS — Frequently Asked Questions
Quick answers to the most common questions about buying EBS stock.
What is Emergent BioSolutions Inc.'s P/E ratio?
Emergent BioSolutions Inc.'s current P/E ratio is 8.6x. The historical average is 24.7x. This places it at the 6th percentile of its historical range.
What is Emergent BioSolutions Inc.'s EV/EBITDA?
Emergent BioSolutions Inc.'s current EV/EBITDA is 3.7x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 11.0x.
What is Emergent BioSolutions Inc.'s ROE?
Emergent BioSolutions Inc.'s return on equity (ROE) is 10.5%. The historical average is 7.3%.
Is EBS stock overvalued?
Based on historical data, Emergent BioSolutions Inc. is trading at a P/E of 8.6x. This is at the 6th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Emergent BioSolutions Inc.'s profit margins?
Emergent BioSolutions Inc. has 47.2% gross margin and 14.8% operating margin. Operating margin between 10-20% is typical for established companies.
How much debt does Emergent BioSolutions Inc. have?
Emergent BioSolutions Inc.'s Debt/EBITDA ratio is 2.7x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.